Companies›Commodities›Chemicals›Chemicals & Petrochemicals

OMKAR PHARMACHEM LTD.

Chemicals › Chemicals & Petrochemicals
₹6.57
at close · 27 Oct 2026
▼ 0.33 (-4.78%)

Latest filings

  1. Routine share dematerialization certificate filed for Q2 FY27 · Compliance
  2. 31st AGM voting results - all three resolutions passed with majority · Board & Shareholder Meetings
  3. 31st AGM held; director re-appointment and related party transactions approved · Board & Shareholder Meetings
All filings ↓
Ask Nexa about OMKAR PHARMACHEM LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Chemicals & Petrochemicals company listed on BSE, reporting revenue of ₹0 Cr over the trailing twelve months.

Market Cap
₹7 Cr
P / E (TTM)
0.2×
EV / EBITDA
38.1×
Div Yield
—
Growth
11.5%▲
Revenue 5y CAGR
PAT -11.3% · EBITDA +50.5%
Quality
3.0%·
ROCE (5y median)
ROE 2.1% (5y median) · margin 36.2%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.22 Cr
Revenue FY21→FY26
1.7×▲
Margin −55.8 pts
₹0 Cr → ₹0 Cr
Cash conversion
1.40×▲
Operating cash ÷ profit · 5 yrs
₹1 Cr on ₹1 Cr
Moves on a normal day
4.79%·
Median daily move
Last 98 sessions · the yardstick for filing-day moves
Where it sits among 66 Commodity Chemicals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#2/50
P/B#3/60
ROCE#49/62
ROE#45/60
Debt / Equity#2/60
EBITDA margin#9/58
Revenue growth#48/54
Profit growth#13/64

Scorecard

Measured from the filed financials, judged against its Commodity Chemicals peers · as of FY26 — not investment advice

Strengths
No borrowings on the balance sheet
lower than 85% of its 60 Commodity Chemicals peers
Over 5 years it reported ₹0.89 Cr of profit and ₹1.25 Cr of operating cash — 1.40×
Profit is converting into cash
Concerns
Profit shrinking over 5 years (−11% a year)
Erratic profits — up in only 2 of the last 5 years
Returns on capital 3.0% (5-year median)
#49 of 62 in Commodity Chemicals on the latest reported figures

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from OMKAR PHARMACHEM LTD.'s filed financials and exchange disclosures

What does OMKAR PHARMACHEM LTD. do?

OMKAR PHARMACHEM LTD. is a Chemicals & Petrochemicals company listed on BSE.

Is OMKAR PHARMACHEM LTD. profitable?

Yes. Over the trailing twelve months OMKAR PHARMACHEM LTD. reported a net profit of ₹0.12 Cr on revenue of ₹0.47 Cr.

Does OMKAR PHARMACHEM LTD. pay a dividend?

Not in the latest reported year — OMKAR PHARMACHEM LTD.'s dividend payout for FY26 was nil.

Is OMKAR PHARMACHEM LTD. debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹0.22 Cr of cash.

Is OMKAR PHARMACHEM LTD. expensive compared with its peers?

On trailing P/E, OMKAR PHARMACHEM LTD. ranks 2 of 50 in Commodity Chemicals — cheaper than 98% of them, against an industry median of 17.4×. This is a position, not a valuation judgement.

How much does the OMKAR PHARMACHEM LTD. share price move in a day?

On a typical session OMKAR PHARMACHEM LTD. moves 4.79% — that is the median absolute close-to-close move across its last 98 trading days. MarketPing measures each filing's price reaction against it.

Where can I track OMKAR PHARMACHEM LTD.'s announcements?

Every NSE and BSE filing by OMKAR PHARMACHEM LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.